A meta-analysis of the relationship between serums metrnl-like protein/subfatin and risk of type 2 diabetes mellitus and coronary artery disease.
Gordon A FernsKiavash FekriMilad Shahini Shams AbadiMahdi Banitalebi DehkordiMohammad-Hassan ArjmandPublished in: Archives of physiology and biochemistry (2021)
There have been inconsistent reports that Metrnl-like protein, a new adipokine, is associated with the risk of metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). A systematic search in PubMed, Scopus, Web of Science, and Google scholar databases were conducted up until 24 November 2020. Ten eligible studies were included in this meta-analysis. The overall results showed that there was no significant association between serum Metrnl levels and risk of T2DM and CAD in patients compared with healthy control (SMD= -0.717 and 95%CI -1.572_0.139, p = .1). However, in subgroup analysis, there was a significant association between a BMI ≥ 25 and the serum level of Metrnl-like protein (SMD= -0.688 and 95%CI -1.348_-0.028 p = .041), indicating a potential inverse connection between serum Metrnl and the adiposity. Further well-designed studies are needed to explain the more subtle roles of Metrnl in metabolic disorders like T2DM and CAD.
Keyphrases
- coronary artery disease
- cardiovascular events
- metabolic syndrome
- percutaneous coronary intervention
- systematic review
- coronary artery bypass grafting
- case control
- end stage renal disease
- glycemic control
- ejection fraction
- newly diagnosed
- insulin resistance
- chronic kidney disease
- body mass index
- public health
- randomized controlled trial
- emergency department
- clinical trial
- aortic stenosis
- weight gain
- cardiovascular disease
- heart failure
- acute coronary syndrome
- adipose tissue
- meta analyses
- patient reported
- artificial intelligence
- data analysis
- uric acid